Loading...
•
Sep 30, 2020
IDEXX Q3 2020 Earnings Report
Achieved revenue growth and EPS growth driven by Companion Animal Group Diagnostics.
Key Takeaways
IDEXX Laboratories reported Q3 2020 revenues of $722 million, a 19% increase. EPS was $1.69, representing 36% growth. The results were driven by Companion Animal Group Diagnostics recurring revenue growth.
Achieved revenue growth of 19% on a reported basis and 18% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 23% reported and 21% organic
High revenue growth supported by sustained strong global recovery in the pet healthcare market
Delivers EPS of $1.69, representing 36% growth on a reported basis and 47% on a comparable constant currency basis, reflecting benefits from high CAG Diagnostics recurring revenue gains and proactive cost controls
Global CAG Diagnostics recurring revenues sustained their growth at high levels through the third quarter reflected in greater than 20% growth early in the quarter and growth closer to 20% in the later part of the quarter, benefiting in part from pent-up demand for wellness diagnostic testing in the U.S.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company is maintaining suspension of full-year 2020 guidance due to the unpredictability of potential future impacts from the COVID-19 pandemic and is not providing preliminary 2021 guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...